Clinical predictors of response to cetuximabchemotherapy in metastatic colorectal cancer
Publication in refereed journal


全文

其它資訊
摘要Objective To identify clinical markers to predict which patients with advanced colorectal cancers are likely to benefit from cetuximabchemotherapy. Design Retrospective review. Setting Oncology unit in a university teaching hospital in Hong Kong. Patients A total of 102 patients with metastatic colorectal cancer treated with cetuximab-chemotherapy. Main outcome measures Correlation of multiple potential clinical predictive factors with tumour response to cetuximab-chemotherapy. Results The objective response rates to cetuximab plus chemotherapy were 53% in patients receiving first-line treatment and 17% in previously treated patients. The univariate analysis indicated that fewer prior lines of chemotherapy (odds ratio=0.36; 95% confidence interval, 0.21-0.63; P<0.01) and development of cetuximab-related grade 3 rash (5.52; 1.62-18.76; P<0.01) were associated with significantly higher response rates. Multivariate analysis confirmed the independent predictive value of the number of prior chemotherapy regimens (odds ratio=0.37; 95% confidence interval, 0.20-0.69; P<0.01) and grade 3 rash (4.65; 1.21-19.29; P=0.03). Conclusions In this cohort of Chinese patients with advanced colorectal cancer, the presence of grade 3 rash and the number of prior chemotherapy regimens were independent predictors of response to cetuximab-chemotherapy. The utility of these clinical markers in clinical practice should be further evaluated together with established biomarkers.
著者Ma A.T.W., Ma B.B.Y., Lei K.I.K., Mo F.K.F., Chan A.T.C.
期刊名稱Hong Kong Medical Journal
出版年份2010
月份8
日期25
卷號16
期次3
出版社Hong Kong Academy of Medicine Press
出版地Hong Kong
頁次207 - 212
國際標準期刊號1024-2708
語言英式英語
關鍵詞Antibodies, Colorectal neoplasms, Epidermal growth factor, Exanthema, Monoclonal, Neoplasm metastasis, Receptor

上次更新時間 2020-17-10 於 01:20